Cytotoxic activity of 2', 2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells

Thyroid

Volumn 10, Issue 10, 2000, Pages 865-869

  Ringel, Matthew D ^a   Greenberg, Max ^a   Chen, Xuwu ^a   Hayre, Nicole ^a   Suzuki, Koichi ^a   Priebat, Dennis ^a   Saji, Motoyasu ^a   Burman, Kenneth D ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GEMCITABINE; PROTEIN P53;

ARTICLE; CANCER CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; THYROID CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUTATION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033768918     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2000.10.865     Document Type: Article

References (45)

1. Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches
2. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group
3. Significance of CD44 gene products for cancer diagnosis and disease evaluation
4. Multimodality treatment in anaplastic giant cell thyroid carcinoma
5. Anaplastic carcinoma of the thyroid: A 24-year experience
6. Chemotherapy for anaplastic carcinoma of the thyroid
7. Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis
8. Chemotherapy and combination therapy in anaplastic thyroid carcinoma
9. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo
10. Concentration and time dependent growth inhibition and metabolism in vitro by 2', 2'-difluoro-deoxycytidine (gemcitabine)
11. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity
12. Preclinical combination therapy with gemcitabine and mechanisms of resistance
13. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu
14. Gemcitabine - A new agent in the treatment of non-small cell lung cancer. A commentary
15. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study
16. The role of gemcitabine in the treatment of other tumours
17. Current concepts in pancreatic cancer: Symposium summary
18. Chemotherapy in the treatment of cancer of the pancreas
19. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
20. Gemcitabine in the treatment of non-small-cell lung cancer
21. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
22. A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer
23. Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy
24. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients
25. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer
26. Radiosensitizing potential of gemcitabine (2', 2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro
27. Radiosensitization of human tumor cells by gemcitabine in vitro
28. Radiosensitization of human solid tumor cell lines with gemcitabine
29. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies
30. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
31. The FRTL-5 thyroid cell strain as a model for studies on thyroid cell growth
32. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
33. Anaplastic thyroid carcinoma: A therapeutic challenge
34. Anaplastic carcinoma of the thyroid
35. Gemcitabine in the treatment of ovarian cancer
36. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: A review
37. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: Evidence of histological subtype-dependent cytotoxicity
38. Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone
39. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
40. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer
41. Synergistic interaction between cisplatin and gemcitabine in vitro
42. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents
43. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model
44. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer
45. Combination chemotherapy studies with gemcitabine